Roy Fox, MD
Critical Care Medicine · Memphis, TNNPI 1972594208
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 510 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations.
Across 510 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$1K
- Boehringer Ingelheim$694
- Sanofi$633
- Genentech USA, Inc.$598
- Insmed, Inc.$538
- plus $4K from 33 others
What the payments were for
- Food & beverage$9,05599%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 71 | $1,479 |
| GSK | 107 | $1,412 |
| Boehringer Ingelheim | 49 | $694 |
| Sanofi | 26 | $633 |
| Genentech USA, Inc. | 32 | $598 |
| Insmed, Inc. | 29 | $538 |
| United Therapeutics Corporation | 23 | $531 |
| Regeneron Healthcare Solutions, Inc. | 18 | $414 |
| Grifols USA, LLC | 24 | $330 |
| Harmony Biosciences LLC | 13 | $259 |
| La Jolla Pharmaceutical Company | 11 | $244 |
| Mylan Specialty L.p. | 16 | $215 |
| Merck | 9 | $167 |
| Novartis | 10 | $152 |
| Aero US Inc | 1 | $139 |
| Intuitive Surgical | 1 | $135 |
| Amgen | 7 | $113 |
| Verona Pharma, Inc. | 6 | $100 |
| Abbott | 1 | $99 |
| Sunovion Pharmaceuticals Inc. | 7 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $88 |
| Tetraphase Pharmaceuticals, Inc. | 4 | $78 |
| Pfizer | 5 | $76 |
| CSL Behring | 3 | $65 |
| Mallinckrodt Enterprises LLC | 4 | $64 |
| Bayer | 4 | $61 |
| AbbVie(2 entities) | 5 | $61 |
| Actelion Pharmaceuticals US, Inc. | 4 | $56 |
| Caris MPI, Inc. | 2 | $42 |
| Mallinckrodt Hospital Products Inc. | 2 | $32 |
| Advanced Respiratory, Inc | 2 | $31 |
| Viatris Specialty LLC | 2 | $28 |
| Baxter Healthcare | 1 | $25 |
| Inogen, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| Mayne Pharma Commercial LLC | 1 | $15 |
| Cumberland Pharmaceuticals, Inc. | 1 | $12 |
| Gilead | 1 | $12 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,135 in reported general payments places this provider in the 85th percentile of 141 critical care medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 270 | $200,476 |
| OfevNintedanib Esylate | 12 | $150,274 |
| TracleerBosentan | 11 | $140,409 |
| Breo ElliptaFluticasone/Vilanterol | 81 | $33,257 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $18,126 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $10,477 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 35 | $5,579 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 21 | $2,659 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 118 | $2,423 |
| Wixela InhubFluticasone Propion/Salmeterol | 15 | $2,124 |
| Azithromycin | 140 | $1,630 |
| Ventolin HfaAlbuterol Sulfate | 15 | $1,596 |
| Montelukast Sodium | 57 | $693 |
| Prednisone | 97 | $447 |
| Methylprednisolone | 17 | $119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,412 | $251,859384 claims |
| Boehringer IngelheimOfev | $694 | $150,27412 claims |
| Actelion Pharmaceuticals US, Inc.Tracleer | $56 | $140,40911 claims |
| AstraZenecaBreztri Aerosphere | $1,479 | $10,47711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 141 critical care medicine providers in Tennessee.
Other critical care medicine in Memphis
- Anthony MattoxMemphis$33K
- Nathan WildsMemphis$19K
- Robert AguillardMemphis$11K
- Kimberly MarshMemphis$11K
- Paul DeatonMemphis$10K
- Garrettson EllisMemphis$9K
- Matthew MabieMemphis$7K
- Steven WoodsMemphis$6K
- William RichardsMemphis$6K
- Michael MundayMemphis$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.